A novel drug that targets a master disease-causing gene can dramatically reduce heart muscle damage after a heart attack and may lead to significantly improved patient outcomes, researchers at the University of New South Wales (UNSW) have shown.
The drug, known as Dz13, specifically targets and neutralises the master regulator c-Jun gene, which is responsible for inflammation and muscle death in the aftermath of a heart attack, trials in preclinical models have found.